Nicholas D. Gillitt, PhD, will assume the role of Chief Executive Officer of The Osmolality Lab, a global leader in osmolality testing and certifications.

Vibrant America Achieves Seven-Year Re-Accreditation Milestone from the College of American Pathologists (CAP)

The Dan Lewis Foundation for Brain Regeneration Research (the DLF) announces the 2023 DLF Prize.

AmplifyBio announces $50M in debt financing to accelerate the expansion of its service offering, supporting the rapid, safe development of next-generation therapeutics

New Integration Delivers 52% Cost Savings and 88% Time Savings in Computational Execution with GPU-accelerated Industry-Standard Tools

P23 Labs, a leading molecular laboratory, is kicking off its 23 Days of Giving series of charitable events running from Dec. 1 to Dec. 23, 2022. Three of these days will be dedicated to gifts to the company's team members and 20 days are for charitable donations to causes from P23 and its partner, Laddia Whittier, who made a generous contribution to make this initiative possible.

After months of experimentation in partnership with some world-class schools of medicine and top-tier diagnostic providers, the much-anticipated T-Cell Test from Hyris, based on innovative qPCR technology, is finally available for the European market with a CE-IVD mark. The new Test will change the way laboratories and diagnostic providers track and monitor T-cell patients' immunity to SARS-CoV-2, leveraging the unique characteristics of the Hyris System™.

A scientific paper recently published in Nature Biotechnology reveals new research regarding how we track and monitor T-cell patients' immunity to SARS-CoV-2, leveraging the unique characteristics of Hyris System™. The study results from a joint effort of an international research team from the Icahn School of Medicine at Mount Sinai, Singapore Duke-NUS Medical School, laboratory diagnostic service providers Synlab, and Hyris.

National ad campaign will encourage patients to ask doctors about superior NGS diagnostics

Baylor Genetics, a joint venture of H.U. Group Holdings, Inc. and the No. 1 NIH-funded genetics program at Baylor College of Medicine in the U.S., and SRL, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc. located in Tokyo, Japan, establish agreement for exome and genome sequencing services.

Expanding their mission-based diagnostics services

Hyris developed a rapid T-Cell test to track patients' immunity levels to SARS-CoV-2 for global clinical and research use after having inked an exclusive licensing agreement with Duke-NUS Medical School. This new solution leverages the power of the renowned HYRIS bCUBE™ and the whole Hyris SystemTM. This disruptive platform enables genetic testing in any setting, at any time, with results available in real-time through its AI-powered platform.

Hyris developed a rapid T-cell test to track patients' immunity levels to SARS-CoV-2 for global clinical use after having inked an exclusive licensing agreement with Duke-NUS Medical School. This new solution leverages the Hyris SystemTM, a proprietary platform that enables genetic testing in any setting, at any time, with results available in real-time through its AI-powered platform.

As new mutations of SARS-CoV-2 keep spreading worldwide, Hyris keeps monitoring its test kits effectiveness, performing routine analysis of SARS-CoV-2 variants to safeguard public health and the product's quality by assessing the potential impact of new strains on sensitivity and specificity.